You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.

Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.

With a commercial presence in 100 countries, we operate through a fully integrated business model from the collection of plasma in our own centers in the United States, Hungary and Germany to fractionation and production in our manufacturing facilities located in Italy, Hungary and the United States.


Updated Bylaws

Kedrion’s Extraordinary Meeting of Shareholders approves the amendment of the Company’s Bylaws

read more 

Shareholders’ Agreement

Sestant Internazionale, Sestant and FSI Investimenti sign a new Shareholders’ Agreement concerning Kedrion

read more 

FY 2017 Results General Investor Call

Friday 25 May 2018 – 09.00 GMT / 10.00 CET

read more 

Financial reports

About Kedrion - Front Image

    Consolidated Financial Statements 2017

    Consolidated First Half Results 2017

    Consolidated Financial Statements 2016

    Consolidated Financial Statements 2015

    Consolidated Financial Statements 2014


Contact & Email alerts

Subscribe to the service in order to receive our news

For more information please contact: